Edition:
United Kingdom

Meridian Bioscience Inc (VIVO.OQ)

VIVO.OQ on NASDAQ Stock Exchange Global Select Market

14.25USD
15 Dec 2017
Change (% chg)

$0.70 (+5.17%)
Prev Close
$13.55
Open
$13.55
Day's High
$14.30
Day's Low
$13.55
Volume
426,177
Avg. Vol
67,043
52-wk High
$18.30
52-wk Low
$10.77

Chart for

About

Meridian Bioscience, Inc. is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $620.38
Shares Outstanding(Mil.): 42.20
Dividend: 0.12
Yield (%): 3.40

Financials

  Industry Sector
P/E (TTM): -- 32.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.01 10.62
ROE: -- 16.85 14.20

BRIEF-Co-Diagnostics Announces Sale Of Molecular Diagnostic Tests

* CO-DIAGNOSTICS, INC. ANNOUNCES SALE OF MOLECULAR DIAGNOSTIC TESTS, INCLUDING ZIKA VIRUS, TO MAJOR CARIBBEAN LABORATORY Source text for Eikon: Further company coverage:

12 Dec 2017

BRIEF-Meridian Bioscience Files For Mixed Shelf Of Up To $100 Million

* MERIDIAN BIOSCIENCE INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source text: (http://bit.ly/2k7rdVf) Further company coverage:

29 Nov 2017

BRIEF-Co-Diagnostics Inc says qtrly loss per share $‍0.33​

* Co-Diagnostics, Inc. Reports Q3 financial results and updates corporate developments

15 Nov 2017

FDA warns Meridian of violations for lead-testing devices

(This Oct. 23 story corrects paragraph 4 to say warning letter, instead of form 483)

24 Oct 2017

CORRECTED-UPDATE 2-FDA warns Meridian of violations for lead-testing devices

Oct 23 The U.S. Food and Drug Administration said on Monday it issued a warning letter to Meridian Bioscience Inc's unit for several federal law violations after inspecting its facility that makes lead-testing devices.

24 Oct 2017

BRIEF-Meridian Bioscience says FDA issued warning letter related to matters at Magellan Diagnostics subsidiary​

* Meridian Bioscience Inc - ‍announced that FDA has issued a warning letter related to matters at its Magellan Diagnostics subsidiary​

23 Oct 2017

FDA warns Meridian of violations for lead-testing devices

Oct 23 The U.S. Food and Drug Administration said on Monday it issued a warning letter to Meridian Bioscience Inc's unit for several federal law violations after inspecting its facility that makes lead-testing devices.

23 Oct 2017

BRIEF-Meridian bioscience comments on preliminary fiscal 2017 operating results

* Meridian Bioscience Inc comments on preliminary fiscal 2017 operating results and provides fiscal 2018 revenue and earnings guidance

19 Oct 2017

BRIEF-MERIDIAN BIOSCIENCE APPOINTS JACK KENNY AS CEO

* MERIDIAN BIOSCIENCE, INC. APPOINTS JACK KENNY AS CHIEF EXECUTIVE OFFICER

10 Oct 2017

BRIEF-Meridian Bioscience introduces expansion of its ImmunoCard STAT! product line

* Meridian Bioscience Inc- ‍Announced expansion of its ImmunoCard Stat! product line with addition of ImmunoCard Stat! FLU A&B​ Source text for Eikon: Further company coverage:

08 Aug 2017

Earnings vs. Estimates